Présentation de l'entreprise
Dyadic International, Inc. operates as a biotechnology platform company dedicated to the development, production, and sale of industrial enzymes and various proteins across both domestic and international markets, with a specific focus on leveraging its proprietary C1 platform for pharmaceutical applications. The firm functions within the healthcare sector, specifically the biotechnology industry, positioning itself at the intersection of industrial manufacturing and advanced drug discovery capabilities. As of the latest reporting period, the company maintains a total market capitalization of $31.91 million and generates annual revenue amounting to $3.09 million, while its total employee count is listed as N/A. These financial metrics indicate a small-cap enterprise operating with a relatively modest revenue base, suggesting a niche market position that relies heavily on the successful commercialization of its technological platform rather than broad-scale industrial volume. The disparity between the small market cap and the specialized nature of its biotechnology operations highlights the high-risk, high-reward profile typical of early-stage platform companies that have yet to achieve significant revenue scaling.
Santé financière
The company reports a trailing twelve-month revenue of $3.09 million against a net income of $-7,364,628, while the EBITDA metric is listed as N/A. The substantial negative gap between total revenue and net income reveals a highly aggressive cost structure where operating expenses significantly outweigh gross profits, resulting in a loss that is nearly 240% of the generated revenue. Free cash flow stands at $-4,524,691, indicating that the company is burning cash to fund its research and development activities, which severely limits its immediate financial flexibility and necessitates reliance on external capital sources or existing cash reserves. The gross margin is recorded at 24.9%, reflecting the cost of goods sold relative to sales, whereas the operating margin plunges to -269.6% and the profit margin reaches -238.3%, both figures demonstrating that non-revenue expenses are driving the company deep into the red. On the balance sheet, the firm holds $7.32 million in cash against $5.06 million in debt, yet the debt-to-equity ratio is extremely elevated at 410.63, signaling a highly leveraged financial structure relative to its shareholders' equity. The current ratio of 2.68 suggests that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for liquidity management despite the negative cash flow trajectory. Return on equity is calculated at -397.8% and return on assets at -44.9%, metrics that collectively reveal that management is currently generating significant negative returns on the capital invested in the business, a common characteristic for biotechnology firms in the pre-profitability phase.
Évaluation de la valorisation
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is reported at -2.74, a negative figure that implies the market is pricing in future losses or expects a long horizon before positive earnings materialize. The price-to-book ratio is exceptionally high at 25.76, indicating that the market values the company's intangible assets, specifically its C1 platform technology, at a massive premium over its accounting book value. The price-to-sales ratio stands at 10.33, and with the EV/EBITDA listed as N/A, these alternative valuation metrics suggest that investors are valuing Dyadic International primarily on its potential future cash flows and intellectual property rather than current profitability. The stock has traded within a 52-week range bounded by a high of $1.35 and a low of $0.65, meaning the current price sits in the lower portion of its recent trading history relative to the high of $1.35. The beta value of 1.21 indicates that the stock's price volatility is approximately 21% higher than the broader market, reflecting the heightened sensitivity of biotechnology equities to sector-specific developments and market sentiment.
Growth & Income
Revenue growth year-over-year is recorded at -30.8%, while earnings growth is listed as N/A, implying that the company is currently in a contractionary phase where declining revenue exacerbates the negative earnings trajectory. Since the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all available capital to reinvest into its biotechnology platform and pharmaceutical development efforts rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company's strategy prioritizes funding its operational burn rate and research initiatives over returning cash to investors, which is a standard approach for capital-intensive biotech firms. Overall, the growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, presenting a scenario where shareholder value is theoretically derived solely from potential future appreciation and the successful commercialization of its industrial enzymes and pharmaceutical products.